Purilogics Awarded NIH Grant to Develop Novel Affinity Membranes for Enhanced mRNA Purification
Purilogics, a company recognized for its best-in-class membrane chromatography technology, development, and commercialization, is excited to announce that it has been awarded a significant grant from the National Institutes of Health (NIH) to support the research and development of first-in-market high-capacity, -selectivity, and -throughput affinity membranes for the purification of mRNA.
With a grant amount of $1.7M from the Small Business Innovation Research (SBIR) program, Purilogics aims to develop mRNA affinity membranes with enabling accelerated purifications for both small and large mRNAs, as well as create and conduct field research on prototypes through industry collaboration.
There has been a rapid surge in the attraction to developing mRNA-based therapies over the last 12 months.
This is particularly exemplified by The FDA’s Emergency Use Authorization of two novel SARS-CoV-2 vaccines. Consequently, the interest in developing novel mRNA technologies to address the challenges accompanied with mRNA drug discovery and industrial production has increased.
Namely, there are significant backlogs in many biologics CMOs and manufacturing facilities where downstream purification has always been a critical bottleneck. When compared to current competing products, Purilogics’ high-throughput prepacked affinity membrane products will dramatically reduce mRNA purification time and improve productivity.
In addition to mRNA affinity membrane products, Purilogics has also developed other innovative membrane technology tools to aid scientists and engineers by addressing a variety of other purification challenges, including antibody, recombinant protein, plasmid DNA, oligonucleotides, and viral vector separations.
(Check out the full Purilogics product lineup here)
Research reported in this press release was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R44 GM144060. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
